Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.230 +0.020 (+1.65%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Pliant has initiated assembly of outside panel of world-renowned experts to review BEACON-IPF trial data 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.